Publicações Científicas

Principais Artigos Científicos

1. von Muhlen CA, Karayev D, Metzger A. Update on autoantibodies in necrotizing myopathies, with special regard to anti-HMGCR. In Conrad K, Andrade LEC, Chan EKL et al (editors), Immunodeficiency, Infection and Autoimmune Diseases: Report on the 13th Dresden Symposium on Autoantibodies, Dresden (Germany), p. 350, 2017.
2. GEO-RA Group. Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey. Clin Rheumatol. 2017 Mar;36(3):485-497.
3. Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327-1339.
4. Chan EK, Damoiseaux J, de Melo Cruvinel W, et al. Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus. 2016 Jul;25(8):797-804.
5. Damoiseaux J, von Muhlen CA, Garcia-De La Torre I, et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights. 2016 Dec;7(1):1.
6. Chan EK, Damoiseaux J, Carballo OG, et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. Front Immunol. 2015 Aug 20;6:412.
7. Wirz EG, Jaeger VK, Allanore Y, et al; EUSTAR coauthors. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis. 2016 Jul;75(7):1285-92.
8. Mihai C, Landewe R, van der Heijde D, et al; EUSTAR co-authors. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis. 2016 Apr;75(4):681-6.
9. Francescantonio PL, Cruvinel Wde M, Dellavance A, et al. IV Brazilian guidelines for autoantibodies on HEp-2 cells. Rev Bras Reumatol. 2014 Jan-Feb;54(1):44-50.
10. Carcamo WC, Calise SJ, von Muhlen CA, et al. Molecular cell biology and immunobiology of mammalian rod/ring structures. Int Rev Cell Mol Biol. 2014;308:35-74.
11. Elhai M, Meunier M, Matucci-Cerinic M, et al; EUSTAR. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013 Jul;72(7):1217-20.
12. Meier FM, Frommer KW, Dinser R, et al; EUSTAR Co-authors. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012 Aug;71(8):1355-60.
13. Covini G, Carcamo WC, Bredi E, von Muhlen CA, et al. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir Ther. 2012;17(5):805-11.
14. Carcamo WC, Satoh M, Kasahara H, et al. Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells. PLoS One. 2011;6(12):e29690.
15. Rigby W, Tony HP, Oelke K, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheum. 2012 Feb;64(2):350-9.
16. Medeiros AM, von Muhlen CA, Gidlund MA, et al. Antibodies against oxLDL and acute coronary syndrome. Arq Bras Cardiol. 2010 Jul;95(1):47-54.
17. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010 Oct;69(10):1809-15.
18. Silveira IG, Burlingame RW, von Muhlen CA, et al. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol. 2007 Nov;26(11):1883-9.
19. Iverson GM, von Muhlen CA, Staub HL, et al. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun. 2006 Dec;27(4):266-71.
20. Mahler M, Kessenbrock K, Szmyrka M, et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol. 2006 Jan;13(1):77-83.
21. Nozawa K, Fritzler MJ, von Muhlen CA, Chan EK. Giantin is the major Golgi autoantigen in human anti-Golgi complex sera. Arthritis Res Ther. 2004;6(2):R95-102.
22. Staub HL, Norman GL, Crowther T, et al. Antibodies to the atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia. Arq Neuropsiquiatr. 2003 Sep;61(3B):757-63.
23. Von Muhlen D, Morton D, Von Muhlen CA, Barrett-Connor E. Postmenopausal estrogen and increased risk of clinical osteoarthritis at the hip, hand, and knee in older women. J Womens Health Gend Based Med. 2002 Jul-Aug;11(6):511-8.

Esta é uma seleção das principais publicações. O Dr. von Muhlen possui centenas de publicações em periódicos médicos internacionais.